AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03060473
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 1 gm PO once
Trial: NCT03060473
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin 250 mg IV every 6 hours for 48 hours followed by 500 mg PO every 8 hours for 5 days.
Trial: NCT00938899
Drug: TMC435350; Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01587833
Drug: Benzodiazepine (BZD) use, defined by ATC codes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BZD prescription during the study period between January 1, 2001 and December 31, 2009
Trial: NCT00477334
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral; two tablets twice a day; single day treatment
Trial: NCT03528421
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days
Trial: NCT03176771
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT-5199 placebo capsules
Trial: NCT02484677
Drug: 5-Fluorouracile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antineoplastic and immunomodulating agents. Blood sampling for pharmacokinetic evaluation
Trial: NCT00655291
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00039208
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04385420
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo film-coated tablet administered via oral route
Trial: NCT00039208
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00641953
Drug: IMX-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (0.3%) 0.5g topically BID to each foot for 4 weeks
Trial: NCT00641953
Drug: IMX-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (0.6%) 0.5g topically BID to each foot for 4 weeks
Trial: NCT00641953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g topically BID to each foot for 4 weeks
Trial: NCT03215810
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered at 60 mg/kg/day IV in 250 mL normal saline (NS) over approximately 2 hours. Cyclophosphamide will be initiated seven days prior to the anticipated TIL transfer, and the precise timing will depend on the rate of in vitro TIL growth. The dose will be based on the patient's body weight, but to prevent undue toxicity, it will not exceed a dose greater than 140% of the maximum ideal body weight per Metropolitan Life Insurance Company, Height and Weight Table.
Trial: NCT00367237
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate 15 mg/week for 15 weeks. Dose can be increased to 20 mg/week at Week 6.
Trial: NCT00000577
Drug: Adrenal Cortex Hormones
RxNorm normalized name: adrenal cortex extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03738735
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the intervention group, the surgical staff will add 120 mL of 23.4% saline to the 3L bags of lactated Ringer's solution, and this new solution will be used for arthroscopic irrigation purposes throughout the rotator cuff repair surgery.
Trial: NCT01381120
Drug: Oxycodone and acetaminophen combination treatment
RxNorm normalized name: acetaminophen / oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
Trial: NCT03132714
Drug: Clarithromycin 500mg
RxNorm normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of Clarithromycin 500mg bid for 7 days
Trial: NCT02349386
Drug: BHR-200 (0.36% transdermal 17β-estradiol gel)
RxNorm normalized name: estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An absorptive hydroalcoholic gel preparation containing 17β-estradiol.
Trial: NCT02349386
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An absorptive hydroalcoholic gel preparation gel of the same ingredients as BHR-200, but without 17β-estradiol.
Trial: NCT00305760
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 250 mg/m2 will be administered one day prior to vaccination (day 0) every three weeks for 6 cycles.
Trial: NCT02536690
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration.
Trial: NCT01192490
Drug: Lubricant
RxNorm normalized name: LUBRICANT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KY Gel will be placed on the cervix and intra-cervically prior to placement of the Mirena
Trial: NCT04428086
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin will be administered as a single oral 10 milligram (mg) dose on Day 1 and Day 7.
Trial: NCT00576602
Drug: Supportive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT01553123
Drug: Iron
RxNorm normalized name: Iron
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once daily, dried ferrous sulfate
Trial: NCT04289285
Drug: Placebo SC Q4W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo every 4 weeks subcutaneously.
Trial: NCT00648830
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single-dose 250 mg immediate-release oral tablets
Trial: NCT00866853
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02026349
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered twice daily over 5 consecutive days for a total of 10 doses.
Trial: NCT00635505
Drug: HFA placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 actuations QID 12 weeks or until use of rescue drug
Trial: NCT04105985
Drug: Kovanaze Nasal Spray
RxNorm normalized name: Kovanaze Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-nasal local anesthetic
Trial: NCT00299858
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients assigned to study group, will receive slow-release theophylline at a dose of 10 mg/kg, titrated to blood levels between 55-110 umol/L, for a period of 4 weeks.~Patients assigned to placebo group will receive identical-appearing placebo tablets for the same period of time.
Trial: NCT02745743
Drug: BAY1251152
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly infusion of BAY1251152 in 21-day cycles.
Trial: NCT02550717
Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose ASA for secondary prevention of cardiovascular events
Trial: NCT01448733
Drug: Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green pea sized amount of Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning in combination with a green pea sized amount of tretinoin 0.05% gel in the evening
Trial: NCT03139500
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo.
Trial: NCT03451071
Drug: Gardasil9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gardasil 9
Trial: NCT00439062
Drug: Roxithromycin
RxNorm normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02604914
Drug: ND0612
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous solution
Trial: NCT02604914
Drug: LCIG
RxNorm normalized name: ColciGel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrajejunal Gel
Trial: NCT00129831
Drug: QAB149
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00914017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill daily for 1 year
Trial: NCT03045172
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT03798236
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solid microcrystalline cellulose
Trial: NCT00297167
Drug: EUR-1008 (APT-1008)
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EUR-1008 (APT-1008) microtablets (5000 lipase units) or minitablets (10000, 15000 or 20000 lipase units) contained in a capsule will be given orally daily in first double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). The capsules could be opened and sprinkled on acidic food and half of the established dose was used with snacks. Treatment duration for first double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
Trial: NCT00297167
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to EUR-1008 (APT-1008) microtablets or minitablets contained in a capsule will be given orally daily in second double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for second double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
Trial: NCT00297167
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to EUR-1008 (APT-1008) microtablets or minitablets contained in a capsule will be given orally daily in first double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for first double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
Trial: NCT01205282
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There will be a 2 week period of placebo run-in.
Trial: NCT03574909
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Size 0 hard gelatin capsules containing 99% of microcrystalline cellulose and 1% of magnesium stearate (Sanitatis®). The capsules contain 198mg microcrystalline cellulose and 2mg of magnesium stearate
Trial: NCT02724761
Drug: Racemic Epinephrine
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 inhalation of 0.5 mL of 2.25% Nebulized Racemic Epinephrine every 8 hours for 24 hours after surgery
Trial: NCT02724761
Drug: Placebo (for racemic epinephrine)
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL of normal saline will be prepared in an identical amber syringe as the drug intervention (racemic epinephrine)
Trial: NCT00297167
Drug: EUR-1008 (APT-1008)
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EUR-1008 (APT-1008) microtablets (5000 lipase units) or minitablets (10000, 15000 or 20000 lipase units) contained in a capsule will be given orally daily in second double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for second double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
Trial: NCT01055379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily for 12 weeks; orally
Trial: NCT04370236
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive up to two once per week subcutaneous injections of Placebo
Trial: NCT02666846
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02666846
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02666846
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00480441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules daily for 2 weeks followed by a 1 week taper
Trial: NCT04003974
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered with food when possible
Trial: NCT02697292
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. Subjects will receive 500 ml normal saline before and after the higher dose infusion of 1g/kg
Trial: NCT03426267
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily
Trial: NCT01308619
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules, oral, one capsule daily in the morning
Trial: NCT01210066
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV fentanyl 1mcg/kg
Trial: NCT00721669
Drug: IMGN388
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMGN388 is a human IgG1 anti-integrin antibody conjugated to the maytansinoid, DM4.
Trial: NCT01220440
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 1 pill x 2 for one week, 2 pills x 2 for one week.
Trial: NCT02947763
Drug: mixture of metronidazole, ciprofloxacin, and minocycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placement of intracanal medication
Trial: NCT04002089
Drug: Exparel Injectable Product
RxNorm normalized name: Exparel Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine liposome injectable suspension
Trial: NCT03697226
Drug: Topical ABI-1968
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple Doses of Topical ABI-1968 Cream with 4 once weekly doses administered in up to 5 Cohorts
Trial: NCT02883543
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy is given by intravenous administration. Three regimens are available in this study.~Regimen 1: etoposide 75mg/m2 d1-5 + cisplatin 75 mg/m2 day1/ day1-2.~Regimen 2: docetaxel 75mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2.~Regimen 3: pemetrexed 500mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2
Trial: NCT03033914
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin: 25 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
Trial: NCT02528448
Drug: Plasma-lyte
RxNorm normalized name: Plasma-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous 1 hour infusion of plasma-lyte 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
Trial: NCT02528448
Drug: 0,9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous 1 hour infusion of 0,9% saline 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
Trial: NCT02711462
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Cohorts 1 and 2, up to 1 subject will receive placebo. In all other Cohorts (Cohorts 3 to 11), up to 2 subjects will receive placebo.
Trial: NCT01186770
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arms.
Trial: NCT01222247
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.
Trial: NCT03722303
Drug: Steroid Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care non-operative treatment for the treatment of Carpal Tunnel Syndrome
Trial: NCT02522117
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were assigned to two groups; one of them received oral atorvastatin (study group), and the other homologated placebo (control group) for 4 weeks before transplant. Then IL2, IL6, TNFalpha and HLA levels were assessed in the recipient's kidney graft by visual analog scale at prior reperfusion, and after 3 and 12 months.
Trial: NCT03005288
Drug: BYM338 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion every four weeks
Trial: NCT00333515
Drug: Human Butyrylcholinesterase (HuBChE) derived from human plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration via IV infusion at a rate of 50 mg/min (2 mL/min)
Trial: NCT00333515
Drug: Placebo: Normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration via IV infusion at a rate of 50 mg/min (2 mL/min)
Trial: NCT00622765
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule twice daily
Trial: NCT00622765
Drug: R256918
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg capsule twice daily
Trial: NCT00622765
Drug: R256918
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg capsule twice daily
Trial: NCT00622765
Drug: R256918
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg capsule twice daily
Trial: NCT04995562
Drug: 129Xe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled contrast for MRI
Trial: NCT00511472
Drug: MK-0941
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Titration Scheme #1, MK-0941/matching placebo was initiated at 10-mg q.a.c. dose and increased on a daily basis (Titration Dose \[TD\] Days 1 to 4 of the Titration Phase 1) in 10-mg q.a.c. increments.~Titration Scheme #2 was a flexible-dose titration scheme in which MK-0941/matching placebo was given at a dose determined by a pre-prandial plasma glucose concentration for the subsequent meal on the previous day of administration on Days 1 to 4 of the Titration Phase 2.
Trial: NCT01968005
Drug: Etoreat®(Etodolac-Lidocaine Topical Patch)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01968005
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04212169
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple doses
Trial: NCT00511472
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Placebo (Pbo), 20 mg Pbo, 30 mg Pbo or 40 mg Pbo q.a.c.
Trial: NCT00289211
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02327234
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2x 200mg ibuprofen, single dose, blinded in 00 capsules
Trial: NCT02327234
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lactose filled 00 capsules to match appearance of ibuprofen intervention
Trial: NCT02733133
Drug: Testagen® TDS Testosterone 5% HypoSpray®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topically applied Testosterone Hormone Replacement Lotion
Trial: NCT00340691
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003686
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 5 mg po qid x 4 weeks
Trial: NCT00243243
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion of placebo (sterile water)
Trial: NCT06233708
Drug: Non-Selective Beta-Adrenoreceptor Agonists for Systemic Use
RxNorm normalized name: Non-selective beta-adrenoreceptor agonists for systemic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-selective blocker including Propranolol, Carvedilol PO was prescribed
Trial: NCT01556217
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form= oral suspension, Route= oral administration. Oral suspension to be taken once with 240 mL (8 ounces of water) between 8:00 AM and 10:30 AM.
Trial: NCT00000575
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 100 Og puffs budesonide placebo bid + two 90 Og puffs albuterol prn OR four 2 mg puffs nedocromil placebo bid + two 90 Og puffs albuterol prn.
Trial: NCT02181387
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered every 6 hours by mouth up to 4 doses
Trial: NCT02181387
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no